|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.420 USD | +1.57% |
|
+0.24% | -27.60% |
| 07/07 | RBC Capital Trims CorMedix Price Target to $13 From $14, Maintains Outperform Rating | MT |
| 03/07 | CorMedix Names Elizabeth Hurlburt as Chief Operating, Commercial Officer | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 2L | 65.41T | - | 4.35Cr | 31Cr | |||||
Total Revenues | 2L | 65.41T | - | 4.35Cr | 31Cr | |||||
Cost of Goods Sold, Total | 1L | 3.73T | - | 31.91L | 2.21Cr | |||||
Gross Profit | 42T | 61.67T | - | 4.03Cr | 29Cr | |||||
Selling General & Admin Expenses, Total | 1.63Cr | 2Cr | 3.58Cr | 5.87Cr | 9.61Cr | |||||
R&D Expenses | 1.31Cr | 1.07Cr | 1.32Cr | 39.42L | 1.93Cr | |||||
Amortization of Goodwill and Intangible Assets - (IS) | - | - | - | - | 1.39Cr | |||||
Other Operating Expenses, Total | 2.95Cr | 3.07Cr | 4.9Cr | 6.26Cr | 13Cr | |||||
Operating Income | -2.94Cr | -3.06Cr | -4.9Cr | -2.24Cr | 16Cr | |||||
Interest Expense, Total | -15.94T | -26.52T | -34.3T | -36.4T | -27.82L | |||||
Interest And Investment Income | 14.4T | 3L | 26.82L | 25.79L | 38.46L | |||||
Net Interest Expenses | -1.54T | 3L | 26.48L | 25.42L | 10.64L | |||||
Currency Exchange Gains (Loss) | -21.29T | 37.14T | -28.99T | -30.79T | -52T | |||||
Other Non Operating Income (Expenses) | - | - | - | 5L | - | |||||
EBT, Excl. Unusual Items | -2.95Cr | -3.03Cr | -4.63Cr | -1.93Cr | 16Cr | |||||
Merger & Related Restructuring Charges | - | - | - | - | -1.02Cr | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | 53.64L | |||||
Other Unusual Items | - | - | - | - | -65.01L | |||||
EBT, Incl. Unusual Items | -2.95Cr | -3.03Cr | -4.63Cr | -1.93Cr | 15Cr | |||||
Income Tax Expense | -12.5L | -6L | - | -13.95L | -1.3Cr | |||||
Earnings From Continuing Operations | -2.82Cr | -2.97Cr | -4.63Cr | -1.79Cr | 16Cr | |||||
Net Income to Company | -2.82Cr | -2.97Cr | -4.63Cr | -1.79Cr | 16Cr | |||||
Net Income - (IS) | -2.82Cr | -2.97Cr | -4.63Cr | -1.79Cr | 16Cr | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | 10L | |||||
Net Income to Common Incl Extra Items | -2.82Cr | -2.97Cr | -4.63Cr | -1.79Cr | 16Cr | |||||
Net Income to Common Excl. Extra Items | -2.82Cr | -2.97Cr | -4.63Cr | -1.79Cr | 16Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.75 | -0.74 | -0.91 | -0.3 | 2.25 | |||||
Basic EPS - Continuing Operations | -0.75 | -0.74 | -0.91 | -0.3 | 2.25 | |||||
Basic Weighted Average Shares Outstanding | 3.77Cr | 4.03Cr | 5.09Cr | 5.89Cr | 7.2Cr | |||||
Net EPS - Diluted | -0.75 | -0.74 | -0.91 | -0.3 | 2.04 | |||||
Diluted EPS - Continuing Operations | -0.75 | -0.74 | -0.91 | -0.3 | 2.04 | |||||
Diluted Weighted Average Shares Outstanding | 3.77Cr | 4.03Cr | 5.09Cr | 5.89Cr | 8.03Cr | |||||
Normalized Basic EPS | -0.49 | -0.47 | -0.57 | -0.21 | 1.4 | |||||
Normalized Diluted EPS | -0.49 | -0.47 | -0.57 | -0.21 | 1.26 | |||||
Supplemental Items | ||||||||||
EBITDA | -2.94Cr | -3.05Cr | -4.89Cr | -2.2Cr | 17Cr | |||||
EBITA | -2.94Cr | -3.06Cr | -4.9Cr | -2.22Cr | 17Cr | |||||
EBIT | -2.94Cr | -3.06Cr | -4.9Cr | -2.24Cr | 16Cr | |||||
EBITDAR | -2.92Cr | -3.03Cr | -4.87Cr | -2.18Cr | - | |||||
Total Revenues (As Reported) | - | - | - | - | 31Cr | |||||
Effective Tax Rate - (Ratio) | 4.24 | 1.93 | - | 7.22 | -8.69 | |||||
Current Domestic Taxes | - | - | - | - | 1.28Cr | |||||
Total Current Taxes | - | - | - | - | 1.28Cr | |||||
Deferred Domestic Taxes | - | - | - | - | -2.58Cr | |||||
Total Deferred Taxes | - | - | - | - | -2.58Cr | |||||
Normalized Net Income | -1.84Cr | -1.89Cr | -2.9Cr | -1.21Cr | 10Cr | |||||
Interest on Long-Term Debt | 15.94T | 26.52T | 34.3T | - | - | |||||
Non-Cash Pension Expense | - | - | - | - | 41L | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | - | - | - | - | - | |||||
Selling and Marketing Expenses | - | - | - | 2.87Cr | 3.81Cr | |||||
General and Administrative Expenses | - | - | - | 3Cr | 5.8Cr | |||||
Research And Development Expense From Footnotes | 1.31Cr | 1.07Cr | 1.32Cr | 39.42L | 1.93Cr | |||||
Net Rental Expense, Total | 2L | 2L | 2L | 2L | - | |||||
Imputed Operating Lease Interest Expense | 27.25T | 51.12T | 77.27T | 1L | - | |||||
Imputed Operating Lease Depreciation | 2L | 2L | 1L | 1L | - | |||||
Stock-Based Comp., COGS (Total) | - | - | - | - | 5L | |||||
Stock-Based Comp., R&D Exp. (Total) | - | - | - | - | 7L | |||||
Stock-Based Comp., S&M Exp. (Total) | - | - | - | - | 16.9L | |||||
Stock-Based Comp., G&A Exp. (Total) | - | - | - | - | 1.09Cr | |||||
Stock-Based Comp., Other (Total) | 50.43L | 40.7L | 54.94L | 61.29L | - | |||||
Total Stock-Based Compensation | 50.43L | 40.7L | 54.94L | 61.29L | 1.38Cr |
- Stock Market
- Stocks
- CRMD Stock
- Financials CorMedix Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















